SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Bitcoins selloff amid concerns over a reported Binance security breach is weighing on Strategy shares, with traders debating whether the crypto-market shock signals deeper trouble or a buying opportunity. Concerns about Strategys quarterly results and CFO transition add to the bearish discussion, while some investors expect a rebound.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCaths Medicare add-on reimbursement could decline sharply after the first quarter of 2027 has fueled concern about pricing and CorMedixs largest revenue driver, alongside a steep selloff. Traders disagree on whether the comments signal a lasting revenue threat or are preliminary, DaVita-specific estimates with limited visibility into future reimbursement and utilization.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTX has reached fresh 52-week highs, with traders focused on an expected Q3 earnings report and debating whether the rally reflects BRIUMVI growth expectations or speculative buyout hopes and short covering. The buyout talk remains unconfirmed, and the earnings date has not been officially confirmed.

Whirlpool Corp. engages in the manufacturing and marketing of home appliances. Its products include home laundry appliances, refrigerators and freezers, cooking appliances, home dishwashers, and room air-conditioning equipment, mixers, and portable household appliances. The firm's brands include Whirlpool, KitchenAid, Maytag, Consul, Brastemp, Amana, Bauknecht, JennAir, and Indesit. It operates through the following geographical segments: Major Domestic Appliances (MDA) North America, Major Domestic Appliances (MDA) Latin America, Small Domestic Appliances (SDA) Global, and Others. The company was founded by Emory Upton, Fred Upton, and Louis C. Upton on November 11, 1911 and is headquartered in Benton Harbor, MI.

Whirlpool Corp.

Whirlpools weak Q1 results, sharply reduced full-year outlook and dividend suspension have driven attention, as the company cited recession-level appliance demand and blamed the Iran war and collapsing consumer confidence. Many traders are alarmed by the worsening outlook and debt burden, while some see the selloff as an overreaction and are buying for a possible rebound.

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

CVS Health Corp

Weaker 2027 Medicare Advantage star ratings for Aetna are driving concern about lost bonus payments and future margin pressure. Traders are comparing CVSs weakness with Humanas rally on improved ratings, while debating whether the setback is already priced in.

Corvus Pharmaceuticals, Inc. engages in the development of product candidates for the treatment of cancer and immune-mediated and inflammatory diseases. Its product candidates include soquelitinib, an ITK inhibitor, ciforadenant, an adenosine A2A receptor antagonist, and mupadolimab, a B cell-activating anti-CD73 antibody. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Traders are focused on a possible update on Corvuss ALPS program around the ASH abstract release and a company call, though the timing and whether the data will be disclosed remain uncertain. Optimism about a potential catalyst is countered by concerns over past delays, managements limited updates and heavy short interest.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

RASONQUE (daraxonrasib), Revolution Medicines pancreatic cancer therapy, remains the main focus: traders cite its Phase 3 survival results and FDA approval as support for the companys commercial and broader RAS-drug pipeline prospects. Discussion is also divided over valuation and efficacy across KRAS subtypes, with some traders pointing to competition from selective G12D drugs such as Verastems VS-7375.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances updated NSCLC trial results and shift toward biomarker-selected lung-cancer studies are driving attention: the overall response rate was 24.6%, while a retrospective subgroup showed a stronger signal, but the lung-cancer filing is expected in 2027 and durability remains uncertain. Traders are divided between viewing the selloff as an overreaction to promising precision-treatment data and seeing a narrower, delayed opportunity compounded by managements confusing presentation.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apples fiscal fourth-quarter earnings report is the focus, with traders debating whether its premium valuation can be justified amid memory-cost pressures and concerns about iPhone demand and upgrade cycles. Some expect a sharp post-report drop, while others view Apples restrained AI spending and relative resilience during the tech selloff as supporting its safe-haven appeal.

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Arrowhead Pharmaceuticals Inc.

Arrowheads interim ARO-MAPT resultsshowing substantial tau reduction and supporting subcutaneous delivery of RNAi to the central nervous systemare a major focus. Traders broadly view the data as encouraging platform validation, but many are frustrated that the share price has not reflected the positive results and debate whether the weakness is market-driven or a sell-the-news reaction.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Palantir's Growth Story Gets a Goldman Boost: ETFs to Consider

Palantir's rally gains steam as Goldman Sachs turns bullish and Dan Ives names it a top tech pick for 2027. Here we present some ETFs that offer exposure to PLTR.

Should You Invest in the First Trust Indxx Aerospace & Defense ETF (MISL)?

Boeing Lands $20B Navy Deal for Next-Gen Fighter Jet: ETFs to Watch

Boeing's $20B Navy win adds to a string of defense and commercial orders. Here are the ETFs offering exposure to the aerospace giant.

Defense ETFs in Focus Amid Earnings, Conflict and Military Spending

Defense ETFs are gaining attention as solid Q2 earnings, rising military spending and escalating Middle East tensions strengthen the sector's outlook.

GE Stock Heads For Second Weekly Loss Despite Strong Q2 And Outlook: Retail Cries 'Buying Opportunity'

Equity

GE Aerospace CEO Larry Culp highlighted strong demand in commercial aviation and defense.


Beyond Lockheed's $3.5B Buyout: Naval Consolidation Reshaping Defense ETFs

LMT's $3.45B Ultra Maritime deal highlights a broader naval defense consolidation wave, making defense ETFs a diversified way to gain sector exposure.

Defense ETFs Likely to Rally as Trump Plans Spending Boost

Rising geopolitical tensions and Trump's defense push are fueling a long-term rearmament trend. One can explore ETFs to benefit from this outlook.

First Trust Exchange-Traded Fund - Indxx Aerospace & Defense ETF

Bullish Sentiment

<ul class="summary-bullets"><li>GE reported 24% revenue growth to $12.63 billion in Q2, beating estimates.&nbsp;</li><li>Larry Culp highlighted operational gains from FLIGHT DECK and progress in hybrid-electric flight technology.&nbsp;</li><li>Jim Cramer viewed the stock’s decline as a buying opportunity.&nbsp;</li></ul>GE Aerospace (GE) stock is headed for a second straight weekly drop despite strong fiscal second-quarter (Q2) results and a better outlook with retail investors seeing the decline as a chance to buy, supported by strong demand, improved operations and future growth in aviation and defense.<h2 class="st-heading-2">GE Aerospace CEO Sees Aviation Boom Continue With Higher Sales&nbsp;</h2>GE Aerospace CEO Larry Culp pointed to continued demand across commercial aviation and defense markets. He pointed to higher orders, revenue expansion, stronger earnings and improved cash generation as evidence of momentum heading into the rest of the year.“We expect a gradual return to modest departures growth in the second half. And combined with our Commercial Services backlog of roughly $170 billion, we remain well positioned for services growth in 2026 and beyond,” said Culp.&nbsp;Culp said GE Aerospace’s FLIGHT DECK operating system has helped improve manufacturing efficiency, quality and delivery performance. He also added that GE Aerospace is advancing future aviation programs, including hybrid-electric flight research through the NASA Electrified Powertrain Flight Demonstration initiative.GE Aerospace posted a 24% year-on-year increase in Q2 revenue, reaching $12.63 billion, beating analysts’ expectations of $11.89 billion. The company also reported adjusted earnings of $2.02 per share, ahead of the Street’s view of $1.86 per share, according to Fiscal AI data.&nbsp;The company raised its&nbsp;2026 operating profit guidance to $10.55 billion to $10.75 billion, from the prior figure of $9.85 billion to $10.25 billion.&nbsp;<a href="https://stocktwits.com/symbol/GE">GE Aerospace stock&nbsp;</a>edged 0.02% lower overnight, ahead of Friday.&nbsp;<h2 class="st-heading-2">Cramer Sees GE Aerospace Pullback As Buying Opportunity&nbsp;</h2>“Mad Money” host Jim Cramer&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/2026/07/16/jim-cramer-pullback-aerospace-giant-buying-opportunity.html?__source=iosappshare%7Ccom.stocktwits.StockTwits.STShareExtension">reportedly</a> said investors are overlooking GE Aerospace’s strong quarterly performance and called the recent stock decline a potential buying opportunity. He said the company’s $210 billion backlog, solid demand and operational improvements outweigh concerns over slower order growth.&nbsp;GE Aerospace will display its aviation technologies at the 2026 Farnborough International Airshow, showcasing its Flying Test Bed, hybrid-electric aircraft and emerging technologies, including AI-enabled tools and the RISE Open Fan model.&nbsp;<h2 class="st-heading-2">What Are GE Retail Traders Saying</h2>On Stocktwits, retail sentiment around the stock improved to ‘extremely bullish’ from ‘bullish’ territory the previous day with a 300% jump in message volume over 24 hours.&nbsp;A user&nbsp;<a href="https://stocktwits.com/DemsRuinBigCities/message/659238305">said</a>, “Down day. Disappointed by this reaction but the bright side is this is a good opportunity.&nbsp;Another user&nbsp;<a href="https://stocktwits.com/zeee/message/659241429">said</a>, “this reaction is ridiculous!!&nbsp; Farnborough next week will show the future on electrification securing yet another market.”A third user&nbsp;<a href="https://stocktwits.com/BradBreath/message/659218162">said</a>, “A BUYING OPPORTUNITY EXSIST !”GE stock has gained over 12% year-to-date.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ko-stock-in-focus-coca-cola-s-fairlife-halts-us-production-after-ransomware-attack/cZZ77njR7tW">KO Stock In Focus: Coca-Cola’s Fairlife Halts US Production After Ransomware Attack</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

GE Aerospace logo is seen at the International Defence Industry Exhibition in Kielce, Poland.

GE Aerospace (GE) stock is headed for a second straight weekly drop despite strong fiscal second-quarter (Q2) results and a better outlook with retail investors seeing the decline as a chance to buy, supported by strong demand, improved operations and fut

GE Aerospace

Invesco Aerospace & Defense ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Fundamentals

Info

MISL First Trust Exchange-Traded Fund - Indxx Aerospace & Defense ETF

Fundamentals

Latest MISL News